Glympse Bio is pioneering an in vivo sensing technology dedicated to transforming disease monitoring. The company has built a product engine enabling rapid development of tunable and bioengineered activity sensors for multiple indications including fibrosis, cancer, immunology and infectious diseases. The technology has been validated in 10 different diseases using multiple delivery methods and a broad range of analytical readouts. Glympse aims to improve healthcare globally by serving the needs of patients, clinicians, researchers, drug developers, and payors to help advance the science and our understanding of human diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/09/18 | $22,000,000 | Series A |
ARCH Venture Partners Charles River Ventures Gilead Sciences GreatPoint Ventures Heritage Provider Network Inevitable Ventures LS Polaris Innovation Fund Rivas Capital Yonghua Capital | undisclosed |
| 07/16/20 | $46,700,000 | Series B |
ARCH Venture Partners Catalio Capital Management CRV DNS Capital Gilead Sciences GreatPoint Ventures LS Polaris Innovation Fund New Leaf Venture Partners Section 32 Temasek Waterman Ventures | undisclosed |
